Katherine Nathanson, MD
Investigators recently evaluated the genetic profiles of 160 breast and ovarian cancers associated with germline mutations inBRCA1andBRCA2anddetermined that there is a relationship between the genetics ofBRCA1/2 mutations and the risk of resistance to platinum-based chemotherapy. Historically, it had been thought that allBRCA1- andBRCA2-associated tumors lose the second genetic allele; however, the findings showed that this was not true.
In an interview withTargeted Oncology, the study’s senior author Katherine Nathanson, MD, a deputy director of the Abramson Cancer Center, and director of Genetics at Basser Center for BRCA, University of Pennsylvania, discussed how the genetics ofBRCA1/2-associated tumors impacts tumor development and response to treatment.
TARGETED ONCOLOGY:Can you please provide an overview of this research?
Nathanson:We looked at breast and ovarian cancers, first using the data from The Cancer Genome Atlas (TCGA) and then using our local data from the University of Pennsylvania. These were all breast and ovarian cancers, specifically from patients who carriedBRCA1andBRCA2mutations.
The goal of the research was to characterize tumors from women who haveBRCA1andBRCA2mutations. Although that had been done on the small scale, it hadn’t yet been done on a very large scale. We ended up investigating a total of 160 tumors associated withBRCA1andBRCA2mutations, with 100 from TCGA and 60 that were looked at locally at the University of Pennsylvania. Of those, we looked at 94 ovarian cancers and 76 breast cancers.
The dogma had been that allBRCA1- andBRCA2-associated breast and ovarian cancers lost the second allele or the wild-type allele. We were somewhat surprised to find that they didn’t all lose the second allele. It was much more striking forBRCA2-associated tumors than for tumors associated withBRCA1.
ForBRCA1mutations, most of them lost the second allele, but some did not. However, forBRCA2, a substantial proportion did not lose the second allele or the wild-type allele.
We then went on to see if there were any differences between those tumors that retain the second allele and those that lose the second allele. We found differences that were quite significant in terms of whether they had homologous recombination deficiency or whether they had aBRCA-associated mutational signature.
We also looked at mutations associated with those that either did or did not retain the second allele and, surprisingly, found some significant differences in mutation patterns, particularly aroundp53. Those patients who retained the second allele were less likely to havep53mutations.
Finally, we looked at the outcomes of whether they retained the second allele. Ovarian cancer is easier to investigate in this context because most ovarian cancer diagnoses are at relatively late stages; therefore, there is a consistent time of diagnosis. There is also consistent treatment since most patients with ovarian cancer get platinum-based treatment.
We found that if patients retain the wild-type allele, they are equally likely to respond to platinum-based therapy as if they did not carry aBRCA-mutation at all. However, those patients who hadBRCA1orBRCA2mutations and lost the second wild-type allele, were much more likely to respond to platinum-based regimens.
However, we did not see the same thing with breast cancer. In fact, we saw better outcomes with breast cancer. The problem with breast cancer is that patients are treated at different stages with different treatments making it harder to generalize based on that. However, we are able to generalize with ovarian cancer and say that if you retained a second allele ofBRCA1orBRCA2, you are unlikely to respond to platinum therapy. This also led us to believe that it may be unlikely to respond to PARP inhibitors, as well.
TARGETED ONCOLOGY:Can you elaborate on how this research affects determining treatments?
Nathanson:The findings affect determining treatments in 2 ways. The first is that if you retain the second allele, you are unlikely to respond to DNA-damaging agents. We particularly looked at platinum-based regimens because that was the data we had, but this could be generalized.
The other important finding is that this can be looked at quite simply in a clinical setting. Since it is easily generalizable, it could be examined in context with trials without doing additional work beyond what is normally done already.
TARGETED ONCOLOGY:What are the next steps following this research?
Nathanson:One thing we don’t know is whether this is true for otherBRCA-associated tumors. We looked at breast cancer and ovarian cancer, but could this be true for prostate cancer or pancreatic cancer? What's happening for other tumor types?
Beyond looking at other tumor types, you can see whether there are other associations with how immunogenic the tumors are. One of the things that would be interesting to find out is if the patients who have not lost the second allele and are less likely to respond to platinum-based treatment, PARP inhibitors, or DNA-damaging agents, may in turn be more likely to respond to checkpoint blockade agents.
TARGETED ONCOLOGY:What are the key, take-home messages from this research?
Nathanson:The main takeaway is that there is an underappreciation of the number of tumors that have not lost the second allele, particularly forBRCA2-associated tumors, and the impact that appears to have on the tumor development and tumor response to therapy.
This is a surprising finding. I would not have thought in advance that we would have identified such a high percentage of tumors that had not lost the second allele, since it goes against dogma.
Maxwell KN, Wubbenhorst B, Wenz BM, et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers [published online ahead of print]. Nature Comm. 2017;8(1). doi:10.1038/s41467-017-00388-9.